Navigation Links
Landauer, Inc. Reports Fiscal 2013 Third Quarter Results
Date:8/5/2013

e incurred in the prior period and service cost reductions of $0.3 million.

During the third quarter of 2013, it became apparent that anticipated revenue trends in our Medical Products reporting unit were not being achieved to the extent forecasted.  Early budget reviews also indicated future sales growth may be less than expected.  We updated the forecasted results of operations for our Medical Products operating segment based on the most recent financial results and our best estimates of future operations. The updated forecast reflects a slower growth in revenues for the Medical Products segment due to anticipated continued pricing pressures from certain competitors greater than the anticipated growth from existing and new product sales.
We recorded a $22.7 million pretax charge for the impairment of goodwill to reduce the carrying value of goodwill in our Medical Products segment. The impairment charge is non-cash in nature and does not affect the Company's liquidity or debt covenant compliance.

Operating loss for the third fiscal quarter of 2013 was $16.8 million, a decrease of $26.0 million, compared with operating income of $9.2 million for the third fiscal quarter of 2012. Operating income, adjusted for the goodwill impairment charge for the third fiscal quarter of 2013, was $6.9 million.

The effective tax rate for the third fiscal quarter of 2013 and 2012 was 21.6% and 23.0%, respectively. The decrease in the effective tax rate was due primarily to benefits from U.S. foreign tax credits.  Without impairment of goodwill the effective tax rate would have been 20.9% for the third fiscal quarter of 2013, a decline over the prior year's tax rate due primarily to benefits from U.S. foreign tax credits.

Net loss for the third fiscal quarter ended June 30, 2013 was $13.8 million, or $1.46 per diluted share, compared to net income of $6.6 million, or $0.69 per diluted share, in the same period last year. The decrease in n
'/>"/>

SOURCE Landauer, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Landauer, Inc. Declares Regular Cash Dividend
2. Landauer, Inc. Reports Fiscal 2013 Second Quarter Results
3. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Second Quarter 2013 Results
4. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
5. Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
6. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Fourth Quarter And Full Year 2012 Results
7. Landauer, Inc. Appoints Ronald Zilkowski To Vice President, Corporate Controller And Chief Accounting Officer
8. Landauer, Inc. Appoints Peter Cempellin To President Of Landauer Radiation Measurement
9. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
10. PDI Reports 2013 Second Quarter Financial Results
11. U.S. Orthopedic Biomaterials Market & Global Biomaterials Industry Reviewed by Products and Applications in New Research Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and ... Interconnects and Packaging (EMIP) Division. "I am ... general management and business development experience, especially in the ... important contributions to the continued growth and success of ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. ... provide a corporate update and report second quarter 2014 ... on Friday, August 1, 2014. That same day, Arena ... a.m. Eastern Time (5:30 a.m. Pacific Time). ... 877.643.7155 for domestic callers and 914.495.8552 for international callers. ...
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... , NEW YORK, ... ) today announced updated efficacy and safety data as ... of KRX-0401 (perifosine) in combination with bortezomib (Velcade(R)) (+/- ... the study entitled "A Multicenter Phase 1/2 Study Evaluating ...
... , , ... its complete workflow management system, DoseEdge(TM), during this week,s ... integrated system for improving patient safety and pharmacy efficiency ... activities. The technology fits easily into current pharmacy practice ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3
(Date:7/27/2014)... 27, 2014 The constant expansion of ... in demand for enterprise video. Additional factors that have ... in areas such as corporate communication, learning and development, ... to all these factors the enterprise video market value ... to reach $35.57 billion in 2018 with a compound ...
(Date:7/27/2014)... 27, 2014 This is a ... Chinese Dutasteride (CAS 164656-23-9) industry. The report firstly ... including its classification, application and manufacturing technology. The ... of Dutasteride (CAS 164656-23-9) listing their product specification, ... The report further analyzes quantitatively 2009-2014 global and ...
(Date:7/27/2014)... 1-Butene is a colorless, combustible gas with ... can be manufactured either through the separation from crude ... Linear alpha olefin (alkene) 1-Butene is a versatile chemical ... important chemicals such as linear light density polyethylene (LLDP), ... 1-Butene market is extremely competitive. The market has several ...
(Date:7/27/2014)... July 27, 2014 As Tylenol ... continue to move forward in federal court, Bernstein ... questioning one of the benefits purportedly associated with ... The research, which appears in the The Lancet, ... all of whom were given either acetaminophen or ...
(Date:7/27/2014)... iFitDress.com, a well-known wedding dress manufacturer ... wedding gowns with sleeves . Furthermore, it has ... are now available with big discounts, from 20 to ... iFitDress.com is one of the big players in the ... new wedding gowns feature fine craftsmanship and charming looks. ...
Breaking Medicine News(10 mins):Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 2Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 3Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 4Health News:Discounted Wedding Gowns With Sleeves Offered At iFitDress.com 2
... are discriminated against.,// ,There are signs in the UK ... bashful about it either, according to sources from the country’s ... to convince them that they should lose weight. The country’s ... of the country’s children are overweight, while 13% are obese. ...
... Russia will hold a beauty contest in which only HIV ... difference will be held in Russia on 1 December 2005, ... positive girls will participate.// The contest has been named ‘Miss ... attitude of the public with regard to the scourge, and ...
... both variant forms of a gene called CYP2A6, which are ... addiction.// The protein product of these genes is believed to ... ,The two identified gene forms are found to decrease ... more specifically found to account for slow processing of nicotine ...
... elderly heart failure patients in United States have better ... advantage over time.// ,Their study findings appear in ... ,Heart failure is the most common cause of ... countries. ,The authors compared process of care and ...
... patients with liver cancer. A cloud of confusion however ... who harbors a liver tumor that cannot be removed ... available for this group of patients. ,Thanks ... now suggested a novel plan for combating these tumors ...
... has found that besides being really harsh on the ears, ... Writing in the latest issue of the European Heart Journal ... mean an increased risk of heart attack. ,Researchers ... study between 1998 and 2001 in 32 hospitals in Berlin. ...
Cached Medicine News:Health News:Tendency To Smoke and Get Addicted Could Run In Families! 2Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Novel Treatment Found To Prolong Survival Of Liver Cancer Patients 2Health News:Irritating Noise Increases Risk Of Heart Attacks 2
... detection and semi-quantitation of ... antigen in serum as ... diagnosis of autoimmune disease. ... performed either manually or ...
... for the detection and quantitation ... nuclear antigens (ENA) [RNP, Sm, ... in human serum. SS-A (Ro) ... in the diagnosis of SLE, ...
... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... human serum. SS-A (Ro) and ... the diagnosis of SLE, subacute ...
... Inc. ENA Screen ELISA test system is ... antibodies to extractable nuclear antigens (anti-ENA) in ... directional insert, this test system is capable ... such as those against Jo-1, Sm, Sm/RNP, ...
Medicine Products: